BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29599206)

  • 1. Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.
    Brusson M; De Grandis M; Cochet S; Bigot S; Marin M; Leduc M; Guillonneau F; Mayeux P; Peyrard T; Chomienne C; Le Van Kim C; Cassinat B; Kiladjian JJ; El Nemer W
    Haematologica; 2018 Jun; 103(6):972-981. PubMed ID: 29599206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
    De Grandis M; Cambot M; Wautier MP; Cassinat B; Chomienne C; Colin Y; Wautier JL; Le Van Kim C; El Nemer W
    Blood; 2013 Jan; 121(4):658-65. PubMed ID: 23160466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM.
    Wautier MP; El Nemer W; Gane P; Rain JD; Cartron JP; Colin Y; Le Van Kim C; Wautier JL
    Blood; 2007 Aug; 110(3):894-901. PubMed ID: 17412890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.
    De Grandis M; Cassinat B; Kiladjian JJ; Chomienne C; El Nemer W
    Am J Hematol; 2015 Jul; 90(7):E137-8. PubMed ID: 25809027
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the
    Brusson M; Cochet S; Leduc M; Guillonneau F; Mayeux P; Peyrard T; Chomienne C; Le Van Kim C; Cassinat B; Kiladjian JJ; El Nemer W
    Haematologica; 2017 Jul; 102(7):e241-e244. PubMed ID: 28385780
    [No Abstract]   [Full Text] [Related]  

  • 6. Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect?
    El Nemer W; De Grandis M; Brusson M
    Thromb Res; 2014 May; 133 Suppl 2():S107-11. PubMed ID: 24862129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
    Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
    J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.
    Chaar V; Laurance S; Lapoumeroulie C; Cochet S; De Grandis M; Colin Y; Elion J; Le Van Kim C; El Nemer W
    J Biol Chem; 2014 Apr; 289(16):11512-11521. PubMed ID: 24616094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
    Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
    Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Red cell and endothelial Lu/BCAM beyond sickle cell disease.
    Colin Y; Rahuel C; Wautier MP; El Nemer W; Filipe A; Cartron JP; Le Van Kim C; Wautier JL
    Transfus Clin Biol; 2008 Dec; 15(6):402-5. PubMed ID: 18948049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation.
    Bartolucci P; Chaar V; Picot J; Bachir D; Habibi A; Fauroux C; Galactéros F; Colin Y; Le Van Kim C; El Nemer W
    Blood; 2010 Sep; 116(12):2152-9. PubMed ID: 20566895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Lu/BCAM glycoproteins in red cell diseases.
    El Nemer W; Colin Y; Le Van Kim C
    Transfus Clin Biol; 2010 Sep; 17(3):143-7. PubMed ID: 20655789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
    Cartron JP; Elion J
    Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
    Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
    Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the interaction between Lu/BCAM and the spectrin-based membrane skeleton in the increased adhesion of hereditary spherocytosis red cells to laminin.
    Gauthier E; El Nemer W; Wautier MP; Renaud O; Tchernia G; Delaunay J; Le Van Kim C; Colin Y
    Br J Haematol; 2010 Feb; 148(3):456-65. PubMed ID: 20092464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
    Odièvre MH; Bony V; Benkerrou M; Lapouméroulie C; Alberti C; Ducrocq R; Jacqz-Aigrain E; Elion J; Cartron JP
    Haematologica; 2008 Apr; 93(4):502-10. PubMed ID: 18322255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered Ca
    Buks R; Dagher T; Rotordam MG; Monedero Alonso D; Cochet S; Gautier EF; Chafey P; Cassinat B; Kiladjian JJ; Becker N; Plo I; Egée S; El Nemer W
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of erythrocyte adhesion to endothelial cells in diseases.
    Wautier JL; Wautier MP
    Clin Hemorheol Microcirc; 2013; 53(1-2):11-21. PubMed ID: 22941965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.